An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines.
AffiliationCancer Research UK Experimental Radiation Oncology Group, Paterson Institute for Cancer Research, Manchester M20 4BX, UK. email@example.com
MetadataShow full item record
AbstractThe aim of this study was to establish the radiosensitising properties of gemcitabine in a pair of related bladder tumour cell lines with differential radiosensitivity. The radioresistant bladder tumour cell line MGH-U1 and its radiosensitive mutant clone, S40b (both p53 mutant), had SF(2) values (surviving fraction at 2 Gy) of 0.98 and 0.64, respectively (P<0.001). Colony-forming assays showed that at 0.01 microM gemcitabine radiosensitisation occurred only in the S40b cell line (dose-modifying factor (DMF)=1.4). At 0.3 microM (killing 50% of cells), both cell lines were radiosensitised; DMF=2.25 and 1.2 for MGH-U1 and S40b, respectively. These data suggest that gemcitabine is an effective radiosensitiser in bladder cancer cell lines, with greater sensitisation in the radioresistant parental line-a feature that should be useful in a clinical setting.
CitationAn evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines. 2004, 90 (2):542-8 Br. J. Cancer
JournalBritish Journal of Cancer
- Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines.
- Authors: Maddineni SB, Sangar VK, Hendry JH, Margison GP, Clarke NW
- Issue date: 2005 Jan 17
- The isolation and partial characterization of a radiation-sensitive clone of a human bladder carcinoma cell line.
- Authors: McMillan TJ, Holmes A
- Issue date: 1991 Dec
- Involvement of p53 in gemcitabine mediated cytotoxicity and radiosensitivity in breast cancer cell lines.
- Authors: Salem SD, Abou-Tarboush FM, Saeed NM, Al-Qadasi WD, Farah MA, Al-Buhairi M, Al-Harbi N, Alhazza I, Alsbeih G
- Issue date: 2012 May 1
- The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines.
- Authors: Pauwels B, Korst AE, Pattyn GG, Lambrechts HA, Kamphuis JA, De Pooter CM, Peters GJ, Lardon F, Vermorken JB
- Issue date: 2006 May 30
- Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer.
- Authors: Kielb SJ, Shah NL, Rubin MA, Sanda MG
- Issue date: 2001 Aug